A Pharmacoeconomic Analysis of Phosphate Binders Cost-Effectiveness in the RISCAVID Study

作者：Panichi Vincenzo^*; Rosati Alberto; Di Giorgio Adriana; Scatena Alessia; Bigazzi Roberto; Grazi Giovanni; Migliori Massimiliano; Paoletti Sabrina; Rizza Giovanni Manca; Casani Aldo; Sgambato Alessandro; Ruggeri Matteo

来源：Blood Purification, 2015, 39(1-3): 174-180.

DOI：10.1159/000369957

• Sevelamer
• Calcium binders
• Chronic kidney disease-mineral bone disease syndrome
• Stroke
• Cardiovascular death
• Phosphate
• Calcium

Background: A pharmacoeconomic analysis of the RISCAVID database aimed at assessing the cost effectiveness of phosphate binders in preventing CV mortality and morbidity over 7 years was performed. Methods: Morbid or fatal events occurring in 750 chronic HD patients were recorded. Statistical analysis evaluated the distribution of variables and the effect of sevelamer on survival. A cost-effectiveness evaluation was performed using a probabilistic model based on a Markov chain. Results: Multivariate analysis showed that treatment with sevelamer was associated with a reduced stroke incidence by 52% (p = 0.04) and reduced levels of C-reactive protein (p < 0.01). Cost-effectiveness evaluation evidenced a 33% decrease in hospital-days for patients treated with sevelamer, with and without comorbidities compared to patients undergoing calcium binders treatment. Conclusion: Treatment with sevelamer was associated with a reduced risk of stroke in HD patients, with a clear saving on disease-related costs for the Italian National Healthcare System.

• 出版日期2015